ASMA predicts for pre-treatment liver biopsy and delays normalisation of ALT during the first 12 weeks of therapy with pegylated interferon and ribavirin but has no impact on SVR

被引：0
|
作者：
Lim, Eu Jin [1 ]
Clements, Amy E. [2 ]
Lubel, John S. [1 ]
机构：
[1] Eastern Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[2] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2012年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：85 / 85
页数：1
相关论文
共 7 条
  • [1] Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-α and ribavirin
    Takaki, Shintaro
    Kawakami, Yoshiiku
    Imamura, Michio
    Aikata, Hiroshi
    Takahashi, Shoichi
    Ishihara, Hiroto
    Tsuji, Keiji
    Aimitsu, Shiomi
    Kawakami, Hiroiku
    Nakanishi, Toshio
    Kitamoto, Mikiya
    Moriya, Takashi
    Satoh, Kenichi
    Chayama, Kazuaki
    [J]. INTERVIROLOGY, 2007, 50 (06) : 439 - 446
  • [2] RESPONSE AND PREDICTORS OF RESPONSE, TO PEGYLATED INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C PATIENTS IN SCOTLAND: ALANINE AMINOTRANSFERASE (ALT) AND GAMMA GLUTAMYL TRANSFERASE (GGT) ARE VALUABLE PRE-TREATMENT MARKERS OF AN SVR IN ROUTINE CLINICAL PRACTICE
    Innes, H.
    Hutchinson, S.
    Allen, S.
    Bhattacharyya, D.
    Bramley, P.
    Carman, B.
    Delahooke, T.
    Dillon, J.
    Goldberg, D.
    Kennedy, N.
    Mills, P.
    Morris, J.
    Morris, J.
    Stanley, A.
    Hayes, P.
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2011, 65 : A254 - A254
  • [3] EFFECT OF PEGYLATED INTERFERON OR RIBAVIRIN DOSE REDUCTION DURING TELAPREVIR BASED THERAPY ON SVR12 IN NULL-RESPONDERS AND RELAPSERS WITH ADVANCED LIVER FIBROSIS (ADVEX STUDY)
    Zarebska-Michaluk, D.
    Flisiak, R.
    Janczewska, E.
    Berak, H.
    Dobracka, B.
    Librant-Suska, M.
    Kozielewicz, D.
    Lojewski, W.
    Jurczyk, K.
    Lapinski, T.
    Musialik, J.
    Postawa-Klosinska, B.
    Wroblewski, J.
    Augustyniak, K.
    Dudziak, M.
    Olszok, I.
    Ruszala, A.
    Kryczka, W.
    Pisula, A.
    Horban, A.
    Dobracki, W.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S474 - S474
  • [4] Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy
    Labarga, Pablo
    Pinilla, Javier
    Cachorro, Iban
    del Prado, Yolanda Ruiz
    [J]. REPRODUCTIVE TOXICOLOGY, 2007, 24 (3-4) : 414 - 416
  • [5] Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy (vol 24, pg 414, 2007)
    Labarga, Pablo
    Pinilla, Javier
    Cachorro, Iban
    Ruiz, Yolanda
    [J]. REPRODUCTIVE TOXICOLOGY, 2008, 26 (3-4) : 310 - 310
  • [6] LOW PRE-TREATMENT NUMBERS OF CD4+/PD-1+LYMPHOCYTES AND LOW HCV-SPECIFIC IL-10 PRODUCTION DURING THERAPY WITH PEGYLATED-INTERFERON plus RIBAVIRIN PREDICT RESPONSE IN CHILDREN WITH CHRONIC HEPATITIS C
    Carey, I.
    Bansal, S.
    Mendes, A.
    Subramaniam, P.
    Cebecauerova, D.
    Vergani, D.
    Mieli-Vergani, G.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 50 : E17 - E17
  • [7] LOW PRE-TREATMENT NUMBERS OF CD4+/PD1+LYMPHOCYTES AND LOW HCV-SPECIFIC IL-10 PRODUCTION DURING THERAPY WITH PEGYLATED-INTERFERON plus RIBAVIRIN PREDICT RESPONSE IN CHILDREN WITH CHRONIC HEPATITIS C
    Carey, I.
    Mendes, A.
    Cebecauerova, D.
    Bansal, S.
    Subramaniam, P.
    Tizzard, S.
    Mieli-Vergani, G.
    Vergani, D.
    [J]. JOURNAL OF HEPATOLOGY, 2010, 52 : S266 - S266
1